Drug Trial Radar · NCT04647643
Real-World Safety Analysis of Paclitaxel Devices Used for the Treatment of Peripheral Arterial Disease
Last checked: Nov 19, 2026Latest source record: Feb 14, 2022 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
8,000
Actual
Start
Nov 20, 2020
Primary completion
Dec 31, 2021
Study completion Dec 31, 2021
Sponsor
- Lead sponsor
- Lahey ClinicAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- National Evaluation System for health Technology Coordinating Center; Society for Vascular Surgery Patient Safety Organization
- First posted
- Dec 1, 2020
Design
- Study type
- Observational
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Treatment with paclitaxel-based endovascular devices (PED) has become a common treatment option for patients with peripheral artery disease (PAD) involving the femoral-popliteal artery. However, an aggregate level meta-analysis identified an association between the use of PED and increased all-cause mortality at both two and five-year follow-up intervals, though there are significant limitations of these analyses. Exploration of real-world data has been suggested as a means to further investigate the safety of PED. The current study explores the association of PED and mortality in real-world data using U.S. commercial claims from the FAIR Health data warehouse.
Conditions
- Peripheral Arterial Disease
Interventions
PaclitaxelDrug
Paclitaxel to treat peripheral arterial disease
Primary outcomes
What the sponsor says the trial is designed to measure.
- SurvivalTime frame: 4 years post intervention
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Lahey Clinic, Inc
Burlington, Massachusetts
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.